To determine the performance of positron emission mammography (PEM), as compared with magnetic resonance (MR) imaging, including the effect on surgical management, in ipsilateral breasts with cancer.
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Dedicated high-spatial-resolution positron emission mammography (PEMie, positron emission tomography with detectors specialized for imaging the breast) with fl uorine 18 fl uorodeoxyglucose (FDG) has been shown to have a high PPV of 0.88 and to depict breast malignancies not seen on mammograms and/or US images with overall sensitivity of 90% ( 11 ) . As such, PEM appears to be more specifi c and possibly more accurate than MR imaging, although to our knowledge, a direct comparison has not been performed previously. The purpose of this study was to determine the performance characteristics of PEM, as compared with MR imaging, including the effect on surgical management, in ipsilateral breasts with cancer.
Materials and Methods
This study was funded in part by Naviscan (San Diego, Calif), the manufacturer of the PEM device described herein. All PEM examinations were provided free of charge to participants. One author (W.A.B.) is a consultant for Naviscan, with compensation based on the fair-market value time spent and not tumor remaining in the breast. Such residual tumor may increase the risk of local recurrence, although this risk is markedly decreased when radiation therapy and/or systemic therapy is administered.
It is desirable to accurately map the extent of the tumor before administering treatment to facilitate optimal decision making for the patient and the treating physicians. This may be especially important in young women, in women with dense breasts, in women with invasive lobular histologic fi ndings, or when an extensive intraductal component is present, as residual mammographically occult tumor is more common in these situations ( 2, 5, 6 ) . Assessing neoadjuvant treatment response also depends on accurate measurements of tumor size prior to and following treatment; magnetic resonance (MR) imaging has been shown to be more effective than mammography or clinical examination in this setting ( 7, 8 ) , and tumor size is more accurately depicted by MR imaging than by US ( 9 ) . In a meta-analysis, preoperative contrast material-enhanced MR imaging was shown to depict additional ipsilateral disease in 16% of women with breast cancer ( 5 ). It is not clear, however, whether this examination results in improved patient outcomes. Approximately 1% of women undergo unnecessary mastectomy as a result of preoperative MR fi ndings ( 5 ), although MR imaging-prompted biopsy has high positive predictive value (PPV), with a median PPV of 0.69 across 19 series ( 5 ) . In a single-institution series, MR imaging was believed to have delayed defi nitive surgery for an average of 22 days owing to additional prompted biopsies ( 10 ) .
W
hen patients are appropriately selected, breast-conserving surgery (BCS) followed by radiation (ie, breast conservation therapy) is widely accepted as producing equivalent survival compared with mastectomy in women with newly diagnosed cancer ( 1 ) . Breast conservation therapy is considered desirable when a cosmetically acceptable result can be achieved by means of complete removal of both the tumor and clear margins of excision. The size and extent of breast cancer are frequently underestimated on the basis of clinical examination and mammographic fi ndings, with or without supplemental ultrasonography (US) (2) (3) (4) . When the cancer size is underestimated and the patient has chosen breast conservation therapy, initial surgical margins may be positive for malignancy, requiring reexcision or mastectomy. When the focality of the tumor is underestimated, the margins may be clear, with residual
Implications for Patient Care
PEM is an alternative for women n who cannot tolerate MR imaging.
PEM has improved specifi city n compared with MR imaging and is therefore less likely to prompt unnecessary biopsies.
Review of mammograms together n with MR or PEM images, or both, improves the detection of additional disease.
Advances in Knowledge
Positron emission mammography n (PEM) proved to be complementary to MR imaging in defi ning the preoperative disease extent in the ipsilateral breasts of women with newly diagnosed breast cancer.
Of 388 participants anticipating n breast-conserving surgery, 82 (21%) were ultimately found to have additional tumor foci after all imaging examinations and surgery: 49 (13%) participants had additional disease depicted at MR imaging, 42 (11%) had additional disease depicted at PEM, and 70 (18%) were identifi ed after review of combined conventional (mammographic and ultrasonographic), PEM, and MR images.
Combined conventional imaging n and PEM depicted additional disease in 53 (14%) participantsnot signifi cantly different from the detection achieved with review of combined conventional and MR images (in 59 [15%] participants) ( P = .26).
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After all surgeries, the site investigators documented whether mastectomy had been performed and whether the mastectomy had been appropriate or inappropriate (ie, lumpectomy would have suffi ced) on the basis of the true disease extent. If the mastectomy was inappropriate, the investigators detailed whether the procedure was prompted by imaging fi ndings-and, if so, by which imaging study-or by the patient's preference. Investigators were asked whether the surgical management planned after conventional imaging had been modifi ed (to wider local excision, mastectomy, or excision of a high-risk lesion) owing to PEM or MR fi ndings and whether or not this had proved to be appropriate. Finally, estimates of disease extent on each PEM and MR imaging study were rated as accurate, underestimated, or overestimated (by 2 cm or more in size and/or additional foci). For this analysis, a suspicious lesion that underwent biopsy after study entry and was found to be benign preoperatively was included as an overestimation.
Analysis
Only those lesions that did not undergo biopsy prior to study entry were considered in the analysis, with a separate review of index cancer detection. Lesions assigned a Breast Imaging Reporting and Data System (BI-RADS) score of 4a or higher or 3 with a recommendation for biopsy were considered to be positive for cancer at imaging (ie, imaging positive). Since PEM and MR imaging were performed as diagnostic examinations, lesions assigned a BI-RADS assessment 3 or lower with recommendation for additional imaging or for short-term or routine follow-up were considered imaging negative. Positive truth was defi ned as a diagnosis of malignancy within 1 year on the basis of the most severe histopathologic result for that lesion. High-risk lesions detected at core-needle biopsy (atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, columnar cell change with atypia, radial sclerosing lesion, atypical papilloma) were excised, as were lesions showing benign papilloma in the core-needle Imaging PEM and MR imaging examinations were performed after study enrollment in randomized order, within 5 business days of each other, without regard to timing in the menstrual cycle. Enrolled participants had to agree to undergo any recommended biopsies and/or follow-up imaging, even if they were considering mastectomy. Additional biopsies could not be performed during the interval between MR imaging and PEM.
Data Collection
The fi ndings of conventional imaging (mammography and often targeted US) performed prior to study entry were reviewed with the histopathology results. Independent interpretations of MR and PEM images were performed by different investigators who were blinded to the results of the other examination. There were exceptions to this blinding: In 20 cases, the same investigator interpreted both PEM and MR imaging examinations because clinical care would have otherwise been delayed (with randomization order followed for interpretation); in another nine cases, the interpreting investigator referred to the MR image results while interpreting the PEM study; and in two cases in which the interpreting investigator referred to the PEM study while interpreting the MR images. We included these 31 cases in which the interpretation was not blinded to the other imaging results, but we also calculated results with these cases excluded and found no substantive differences in the conclusions. The investigators had full knowledge of the conventional imaging and prestudy biopsy results. In reviewing each image set (conventional, MR, and PEM), the investigator described the suspected overall extent and focality of the tumor and ascertained whether or not the participant was likely to be a candidate for BCS. Integrated interpretation across all modalities was then performed at the sites by a study investigator to determine the overall extent of suspected disease. Each presurgical and surgical procedure was documented, and the details of the histopathologic correlations are described in Appendix E1 (online). tied to outcomes. This author received a laptop computer from Medipattern (Toronto, Ontario, Canada) and has consulted as a reader for SuperSonic, Imagine (Aix, Provence, France). One author (D.N.) is a previous employee of and holds stock in Naviscan. Another author (J.E.K.) is a current employee of and holds stock options in Naviscan. An author (E.D.P.) who is neither an employee of nor consultant for Naviscan had control of the inclusion of any data and information that might have represented a confl ict of interest for those authors who are or were employees of or consultants for Naviscan. The laboratory of this author receives research support from GE Medical Systems (Waukesha, Wis), Sectra NA (Shelton, Conn), Konica Minolta Medical Imaging USA (Wayne, NJ), and Hologic (Bedford, Mass) and is negotiating a research contract with Naviscan. Two authors (K.S.M., J.P.M.) are employees of Certus International (St Louis, Mo), which served as the central research organization and was paid by Naviscan. The participating sites met the technical and experience requirements, and obtained institutional review board approval, to participate in this Health Insurance Portability and Accountability Act-compliant study. Details regarding the study investigators, inclusion and exclusion criteria, imaging methods, data collection, and statistical analyses are given in Appendix E1 (online) and summarized here.
Participants
Women 25 years of age or older with newly diagnosed invasive and/or intraductal breast cancer detected at coreneedle or vacuum-assisted biopsy (ie, an index cancer) were recruited from six sites and provided written informed consent. To be eligible, the women had to be candidates for BCS on the basis of the recommendation of a breast surgeon and the following criteria: The tumor was confi ned to one quadrant ( , 4 cm in largest overall extent at initial review of prestudy images) and was not believed to involve the skin or chest wall. In women with large breasts, a tumor size of up to 5 cm was allowed. With the most severe diagnosis at study entry per participant considered the index malignancy, 84 (21.6%) of the 388 index cancers were ductal carcinoma in situ (DCIS), 302 (77.8%) were invasive cancers, one was Paget disease of the nipple, and one was pleomorphic lobular carcinoma in situ being treated as a malignancy. Of the 388 participants, 372 (95.9%) had known solitary malignancy at study entry; 14 (3.6%), known multifocal tumor; and two (0.5%), known multicentric tumor (believed to be candidates for double lumpectomy), yielding a total of 404 ipsilateral index cancers. No participants were known to have bilateral cancer.
After all treatment surgeries had been performed, 283 (72.9%) of the 388 ipsilateral breasts had a solitary tumor; 66 (17.0%), multifocal disease; 21 (5.4%), multicentric disease; 11 (2.8%), both multifocal and multicentric tumors; three (0.8%), multiple separate cancers that could not be further classifi ed; and four (1.0%), diffuse tumor throughout the breast. Forty-fi ve (12%) breasts had an extensive intraductal component. Seventy-fi ve (19%) breasts had pure DCIS, and 311 had invasive tumor, with an overall median invasive tumor size of 1.5 cm (range, 0.1-8.0 cm). The median time to initial surgery for the participants with no additional suspicious fi ndings at imaging was 15 days (range, 2-100 days) compared with 22 days (range, 5-76 days) for those with suspicious fi ndings. biopsy specimen. Negative truth was defi ned as a diagnosis of benign lesion or high-risk lesion on the basis of the most severe fi nding at histopathologic analysis, or a probably benign lesion that decreased in size or resolved at any follow-up. For lesions initially considered probably benign, the absence of cancer after biopsy or the absence of a suspicious change after a minimum of 6 months of imaging follow-up (median follow-up, 10.5 months; range, 6.1-19.2 months) was considered negative truth. Similarly, an integrated interpretation of BI-RADS 2 across all modalities or BI-RADS 1 or 2 after additional imaging was considered negative truth.
At the breast level, if any additional malignancy was present and was truepositive at imaging, the breast was considered to have true-positive fi ndings, even if another lesion in that breast was falsenegative or false-positive. A breast with both false-positive and false-negative lesions was classifi ed as a false-negative case at the breast level. An additional description of the statistical analyses is given in Appendix E1 (online). Diagnostic performance characteristics, including sensitivity, specifi city, accuracy, PPV, and area under the receiver operating characteristic curve, were estimated and compared for each imaging modality and for integrated imaging assessments. P , .05 was considered to indicate statistical signifi cance.
Results
A total of 388 eligible women (mean age, 57.8 years; median age, 58 years; age range, 26-93 years), each of whom had one breast with newly diagnosed cancer ( Fig E1 [online] ), completed the study protocol. The median estimated invasive tumor size at study entry was 1.5 cm (range, 0.4-6.9 cm). The median time from routine-view mammography to the fi rst study imaging examination was 30 days (standard deviation, 21 days; range, 0-121 days). Of the 388 participants, 271 (70%) underwent digital mammography and 117 (30%) underwent screen-fi lm mammography prior to study entry. The mean injected dose of FDG was 10.9 mCi (403.3 MBq)
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Berg et al different when the eight probably benign lesions that were not followed up were excluded or when they were considered malignant ( ( Table 5 ), although no difference based on tumor type was seen with PEM. The addition of PEM to MR imaging significantly improved the detection of DCIS, from 22 (39%) of 56 lesions with MR imaging alone to 32 (57%) lesions ( P = .001), and another seven DCIS foci were seen only at conventional imaging review, for an overall sensitivity of combined conventional imaging, PEM, and MR imaging of 70% for the detection of DCIS. MR imaging was more sensitive for detection of invasive cancer than was PEM: Of 37 IDC lesions with or without DCIS, 21 (57%) were seen at MR imaging compared with 12 (32%) that were seen at PEM ( P = .02). The addition of PEM to MR imaging improved the detection of invasive cancer, from 38 (64%) of 59 lesions depicted with MR imaging alone to 43 (73%) lesions ( P = .025). Two high-grade IDC foci with or without DCIS were seen only at conventional image review.
There was no signifi cant effect of investigative site, hormone use, or menopausal invasive ductal carcinoma (IDC) with or without DCIS, three (3%) were combined IDC-invasive lobular carcinoma with or without DCIS, 19 (16%) were invasive lobular carcinoma with or without DCIS, and one (1%) was a metastatic intramammary node. These additional tumor foci had a median size of 0.7 cm (standard deviation, 1.7; range, 0.1-7.3 cm); the nearly purely invasive tumor foci (with , 10% DCIS) had a median size of 0.6 cm (standard deviation, 1.8; range, 0.1-7.3 cm).
Of the 116 malignant lesions that were not known at study entry, 61 (53%; 95% CI: 43%, 62%) were reported as suspicious at MR imaging; this was more than the 47 (41%; 95% CI: 32%, 50%) malignant lesions reported as suspicious at PEM ( P = .04) and much more than the 24 (21%; 95% CI: 14%, 29%) lesions reported as suspicious at conventional imaging review ( P , .001). PEM was also much more sensitive than conventional imaging ( P , .001) ( Table 4 ) . For characterization of the 189 benign lesions, PEM was more specifi c than MR imaging, with 151 (79.9%) of these lesions imaging negative on PEM images compared with 124 (65.6%) imaging negative on MR images ( P = .002), but it was less specifi c than conventional imaging, where 178 (94.2%) of these lesions were imaging negative ( P , .001). Results at the lesion level were not signifi cantly had additional tumor foci in the ipsilateral breast that was not identifi ed with any imaging modality: Eight breasts had 10 invasive lesions with a median size of 0.3 cm (range, 0.1-1.0 cm), and four breasts had DCIS. At evaluation of the 306 breasts without additional cancer, PEM was signifi cantly more specifi c than MR imaging (91.2% versus 86.3%, P = .032) and similar in performance to conventional imaging ( Table 2 ). Accuracy at the breast level was similar across modalities at 80.7%-82.7%. The area under the receiver operating characteristic curve was 0.76 for MR imaging (95% CI: 0.70, 0.82) and 0.72 for PEM (95% CI: 0.66, 0.78) ( P = .37).
Lesion-Level Performance in Detection of Additional Tumor
Fifty (13%) of the 388 women underwent 59 ipsilateral presurgical percutaneous core-needle biopsies after study entry, with 26 (44%) of these procedures yielding malignancies ( Table 3 ) . A total of 305 discrete nonindex ipsilateral lesions were identifi ed: 211 of these lesions underwent biopsy or direct excision, including 116 malignancies, 14 high-risk lesions (fi ve at core-needle biopsy, all excised with no upgrades), and 81 benign lesions. Follow-up imaging fi ndings showed the remaining 94 lesions to be benign. Of the 116 additional malignant foci, 56 (48%) were DCIS, 37 (32%) were Note.-Sensitivity data are based on 386 index lesion sites with residual malignancy confirmed at surgery. Investigators documented that the known (index) malignancy was seen at imaging, that only the biopsy site changes were seen, or that nothing was seen at the site of known tumor. Results were calculated by considering only the tumor to be seen as positive for cancer as well as by considering the tumor or biopsy site to be seen as positive. Specifi city data are based on the 18 sites found to have no residual tumor at surgery. Accuracy data are based on the 404 original lesion sites (386 with residual cancer plus 18 without residual cancer at surgery). Numbers in parentheses are percentages.
* NA = not applicable. Note.-Data are numbers of malignant lesions found at biopsy/total number of lesions biopsy. Numbers in parentheses are percentages. In Total row, numbers in brackets are 95% CIs for percentages.
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* Lesions considered suspicious (ie, imaging positive, BI-RADS 4a or higher, or BI-RADS 3 with recommendation for biopsy) at review of conventional images only, MR images only, PEM images only, or both MR and PEM images. The lesions suspicious on both conventional and MR images are included among the MR lesions, and the lesions suspicious on both conventional and PEM images are included among the PEM lesions. † Biopsy may have been recommended at additional imaging performed after the breast lesion was assigned a score of BI-RADS 3 or lower, a lesion assigned a score of BI-RADS 3 or lower was included in the excised tissue, or the lesion was not identifi ed until surgery. ‡ Included vacuum-assisted biopsy. § Core-needle procedures included two fi ne-needle aspiration biopsies that yielded benign fi ndings: one prompted by MR fi ndings and one performed only after additional imaging. 
Surgical Management
Of 388 study participants, 56 (14%) ultimately required mastectomy on the basis of the extent of disease ( Figure , Fig E2  [online] ). Of these 56 women in whom mastectomy was necessary, 40 (71%) were correctly identifi ed with MR imaging (22 of whom were identifi ed only by MR imaging); 20 (36%) were correctly identifi ed with PEM ( Table 6 ) ( P , .001), 18 were correctly identifi ed with both MR imaging and PEM, and two were correctly identifi ed with PEM only. The disease extent was underestimated on all imaging in 14 participants who eventually underwent appropriate mastectomy, eight (57%) of whom had an extensive intraductal component. Eleven (2.8% of all participants) women underwent inappropriate mastectomy that was prompted by imaging: fi ve cases prompted by MR fi ndings only, one prompted by PEM fi ndings only, and fi ve prompted by both. 
BREAST IMAGING: Positron Emission Mammography vs MR Imaging of Presurgical Ipsilateral Breast Berg et al
PEM and MR imaging were more likely to lead to an underestimation of disease extent when an extensive intraductal component was present than when it was not (for comparison of accuracy between breasts with and those without extensive intraductal component: P = .004 for PEM accuracy, P = .012 for MR accuracy), although MR imaging performed slightly better than PEM in such cases ( Table 8 ) . Cancer-positive margins were much more common in breasts with an extensive intraductal component: 13 (37%) of 35 women with an extensive intraductal component in whom BCS was attempted had positive margins at initial surgery compared with 30 (11%) of 278 women who had positive margins without an extensive intraductal component ( P , .001).
Other factors that increased the like lihood of mastectomy were positive 262 (67%) ipsilateral breasts, underestimated in 85 (22%) breasts, and overestimated in 41 (11%) ( P , .001 that MR imaging was more accurate). In 28 (7.2%) breasts, PEM was more accurate in depicting the extent of disease than was MR imaging, and in 39 (10%) breasts, MR imaging was more accurate than was PEM ( P = .22, not signifi cant). The two examinations were equally likely to lead to overestimation of disease, but MR imaging was less likely to lead to underestimation of disease than was PEM.
Several factors increased the need for mastectomy. When an extensive intraductal component was present, mastectomy was required for 16 (36%) of 45 breasts, compared with 40 (12%) of 343 breasts requiring mastectomy when an extensive intraductal component was not present ( P , .001) ( Table 7 ). Both For 54 (14%) of the 388 women, the local excision was wider than that planned at conventional imaging, and the wider excision was deemed to be appropriate in 33 of these cases ( Table 6 ). Another 20 cases were considered to have had unnecessarily wider local excision prompted by imaging: Nine were prompted by MR imaging only; six, by PEM only; and fi ve, by both. One highrisk lesion (lobular carcinoma in situ and atypical ductal hyperplasia) was suspicious on both PEM and MR imaging, prompting wider local excision.
MR imaging was more accurate than PEM in surgical planning. MR imaging was accurate for 292 (75%) of the 388 ipsilateral breasts, led to an underestimation of disease in 47 (12%) breasts, and led to an overestimation of disease in 49 (13%). The disease extent determined by using PEM was accurate for Note.-Data are imaging detection rates as functions of histopathologic analysis for 211 lesions that underwent biopsy after study entry. NA = not applicable because there were too few entries for P value comparison.
* ILC = invasive lobular carcinoma. † Data are numbers of lesions, with percentages in parentheses. ‡ Integrated assessment of PEM and MR fi ndings, with exclusion of lesions seen only on conventional images. § High-risk lesions were seven atypical ductal hyperplasia lesions, four lobular carcinoma in situ lesions, two atypical lobular hyperplasia lesions, and one radial scar-complex sclerosing lesion.
|| Benign lesions found to be positive at any imaging modality were 19 fi brocystic changes, eight fi broadenomas, fi ve lymph nodes, one papilloma, and one ruptured cyst. Details on 13 benign lesions were not available.
Images obtained in 68-year-old woman who previously underwent right mastectomy for cancer and was noted to have lump in left breast. in lower inner region of breast. Metastatic axillary nodes were suspected at MR imaging. The patient opted for direct mastectomy; histopathologic analysis confi rmed multicentric grade III IDC, the largest of which was 3.0 cm. The second mass was confi rmed to be 1.2-cm grade III IDC with a less than 5% DCIS component. A third 0.7-cm grade III IDC (straight short arrow) noted in the immediate retroareolar region was diffi cult to distinguish from normal nipple enhancement but visible on both PEM and MR images. Two of fi ve sentinel nodes showed metastatic disease. Both PEM and MR imaging correctly depicted multicentric disease that was not seen at mammography.
margins at initial excision or recommendation for mastectomy based on PEM or MR fi ndings ( Table 7 ) . Among the 388 participants, mastectomy was also more likely to be needed in 66 (17%) cases with multifocal disease ( P = .004 for comparison with unifocal disease) and in 39 (10%) cases with multicentric disease than in the cases of solitary tumor ( P , .001) ( Table 7 ) . With MR imaging, the disease extent of 13 (33%) of 39 multicentric tumors was less likely underestimated compared with 24 (62%) multicentric tumors whose disease extent was underestimated with PEM ( P = .015) ( Table 8 ).
In 283 breasts with a solitary tumor, the tumor size was more often accurately determined with MR imaging (223 [78.8%] breasts) than with PEM (210 [74.6%] breasts) ( P = .005), being underestimated by 2 cm or more in 20 (7.1%) breasts with MR imaging and in 36 (13%) breasts with PEM. Initial margins were positive for cancer in 25 (10%) of 245 breasts with solitary tumors for which BCS was attempted initially versus in 11 (22%) of 51 breasts with multifocal tumor ( P = .042) and seven (41%) of 17 breasts with multicentric tumor ( P , .001 for comparison with solitary tumor) ( Table 8 ) for which BCS was attempted initially. Of the subset of 176 solitary invasive cancers with a lower than 10% in situ component, 166 were seen on PEM images; 163, on MR images; and 153, on both. Pearson correlation coeffi cients between tumor size at imaging and at histopathologic analysis for the 153 tumors seen on MR and PEM images were 0.55 for PEM and 0.81 for MR imaging ( P , .001 for greater accuracy of MR imaging).
Discussion
In this prospective trial, we found that among 388 women anticipating BCS, additional tumor was depicted by MR imaging in 13% ( n = 49) of them, by PEM in 11% ( n = 42), and with conventional imaging review in 5.7% ( n = 22). Our MR imaging results are similar to the 16% rate of detecting additional foci in a meta-analysis involving 2610 women with newly diagnosed cancer ( 5 ). We found that 21% ( n = 82) of the 388 women had Table 6 Accuracy 47 (12) 49 (13) 262 (67.5) 85 (22) 41 (11) , .001
Mastectomy 98
65 (66) 17 (17) 16 (16) 49 (50) 42 (43) 7 ( 8 (15) 17 (31) 33 (61) 8 (15) 13 (24) .61
Appropriate, prompted by imaging (70) 7 (35) 1 (5) 12 (60) Excision of high-risk lesion 35 (15) 21 (8.9)
.006
Note.-All data except P values are numbers of lesions, with percentages in parentheses. Conventional imaging refers to mammography and US. We found that conventional image review signifi cantly improved the detection of additional malignancies, with additional ipsilateral tumor foci (all DCIS) in seven participants (1.8%) seen only at conventional image review. Our results suggest that a coordinated review of all breast imaging studies at the time of PEM or MR image interpretation is important for improved diagnosis. Even after the combination of conventional imaging review, PEM, and MR imaging, additional ipsilateral foci remained undetected in 12 (15%) of the 82 women with additional tumors (3.1% of all the women examined), suggesting that there is room for further improvement. This emphasizes the need for caution when making decisions about adjuvant radiation therapy, especially partial breast irradiation, in women with negative imaging results.
The use of MR imaging for preoperative evaluation is under close scrutiny owing to resulting increased rates of mastectomy (10, (12) (13) (14) and treatment delays, which averaged 22 days in one series ( 10 ) , particularly in the absence of decreased rates of repeat surgery ( 10, 15 ) , decreased recurrences ( 16, 17 ) , or improved survival ( 16, 17 ) . Falsepositive results of biopsies prompted by MR fi ndings result in extra testing and stress for the patient, add to costs, and delay treatment. Our reported PPVs of 53% for biopsies prompted by MR imaging and 69% for conventional imaging were within expected ranges for breasts ipsilateral to malignancy ( 5, 18 Note.-Data are summarized for 56 breasts appropriately treated with ipsilateral mastectomy on the basis of disease extent compared with 332 breasts that did not require mastectomy, among 388 study participants. Unless otherwise noted, data are numbers of breasts, with percentages in parentheses.
* ILC = invasive lobular carcinoma. † Numbers in parentheses are age ranges. ‡ Forty-seven invasive tumors with or without DCIS required mastectomy, as did nine participants with pure DCIS. § P = .076 for rate of mastectomy for ILC versus rate of mastectomy for other tumor types.
|| Other includes one case of invasive tubulobular carcinoma and one case of sarcoma arising in phyllodes tumor.
# Median tumor size, in centimeters, with range in parentheses.
** Includes multiple tumors that could not be further classifi ed. † † Three hundred sixteen participants underwent a single surgery; 59, two surgeries; 10, three surgeries; two, four surgeries; and one, more than four surgeries for treatment of ipsilateral breast cancer.
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PEM was slightly lower than previously reported values ( 11 ) but signifi cantly higher than the PPV of MR imaging. Nevertheless, if additional sus picious fi ndings are identifi ed, presurgical biopsy should be performed to confi rm the need for wider excision or mastectomy. An important result was the signifi cantly improved specifi city of PEM (91.2%) compared with the specifi city of MR imaging (86.3%) ( P = .032), with six unnecessary mastectomies prompted by PEM and 10 prompted by MR imaging ( P = .45, not signifi cantly different). In our series, we observed a median 7-day delay in the time to surgery for participants with suspicious fi ndings at imaging compared with those with no suspicious fi ndings. Several factors may have contributed to the reduced sensitivity of PEM in our series. In our study, if the index malignancies had been included, the overall sensitivity of PEM would have been 80.5% (404 of all 502 malignant lesions vs the observed 41% [47 of 116 lesions] we report herein for the detection of unknown malignancies), which is nearly identical to the 80.7% (405 of 502 lesions) sensitivity for the detection of combined index and unknown malignancies with MR imaging ( P = .92). Avril et al ( 19 ) found that the sensitivity of whole-body FDG PET was highly dependent on the size of the breast cancer, with only three (25%) of 12 cancers 1 cm or smaller identifi ed compared with greater than 90% sensitivity for the detection of tumors 2 cm or larger. We found PEM sensitivity increased with increasing size of malignancy in this series. The section thickness of PEM images increases with increasing breast thickness, as 12 sections are always generated with PEM: Section thickness varied from 3 to 8 mm in our current series. As such, the sensitivity of PEM for the detection of smaller lesions may be reduced in larger breasts owing to volume averaging. PEM-guided percutaneous biopsy ( 20 ) 10 (13) 13 (17) 39 (52) 19 (25) 17 (23) . 03 7 In summary, PEM proved to be complementary to MR imaging for defi ning preoperative disease extent in the ipsilateral breast of women with newly diagnosed breast cancer. PEM was more specifi c than MR imaging and less likely to prompt unnecessary biopsies, but MR imaging was more sensitive to additional malignant lesions and more accurate for assessing disease extent and the need for mastectomy than was PEM. An important fi nding, however, was that even the combination of PEM and MR imaging did not fully depict the disease extent, particularly in cases with an extensive intraductal component, multifocal disease, or multicentric disease-that is, the very patient populations anticipated to benefi t most from accurate preoperative assessment of disease extent. Overall, 61 (16%) of the 388 participants had an appropriate change in surgical management based on MR fi ndings; this was more than the 41 (11%) women with an appropriate change based on PEM fi ndings ( P = .003) and fewer than the 71 (18%) women with an appropriate change based on combined PEM and MR fi ndings ( P = .004 for comparison with MR imaging alone). Twenty-fi ve (6.4%) par ticipants had excessive excisions based on MR fi ndings, as did 19 (4.9%) on the basis of PEM fi ndings ( P = .26) and 32 (8.2%) after combined PEM and MR imaging ( P = .023 for comparison with MR imaging alone).
scatter and required coincidence detection. The positioning with earlier versions of the PEM device (used at all but one site) required three hands: This may have reduced the inclusion of very posterior tissues. Indeed, six (1.5%) of 388 index lesions were believed to be outside the fi eld of view on both the craniocaudal and the mediolateral oblique projections. With a fi eld of view of 23 3 17 mm for PEM ( 11 ) , very large breasts require tiling for complete imaging at PEM (noted for 11 [2. 8%] of the 388 participants in the current study), and this may hamper interpretation. Other positioning issues were the most common limitation of PEM, seen in 36 (9.3%) of 388 participants.
Noncalcifi ed DCIS remains problematic. While MR imaging was reported to depict 92% of DCIS lesions in the work of Kuhl et al ( 22 ) , it remains the source of nearly half of all false-negative MR imaging results ( 23 ) . In our series, sensitivity for the detection of additional DCIS foci was relatively low for both MR imaging and PEM, at 39% and 41%, respectively. The addition of PEM to MR imaging signifi cantly improved DCIS detection (to 57%, P = .001 for comparison with MR imaging alone). Another seven DCIS foci were seen only at conventional imaging review. (Across all imaging, sensitivity was 70%.)
There were several limitations to this study, which are discussed more fully in Appendix E1 (online). Because PEM is a recently introduced technology, surgeons may have been hesitant to directly excise fi ndings that were seen only on PEM images, particularly without initial core-needle biopsy, and PEM-guided core biopsy was not available until late in the protocol. While we used explicit criteria to determine eligibility for BCS, the amount of tissue removed, including full mastectomy, is a complex decision based on a combination of medical, cosmetic, surgical, and participant concerns. The strict attribution of surgical management to any particular imaging modality, combination of modalities, or patient wishes was, at times, challenging. Finally, not evaluating the infl uence of fi ndings from the contralateral breast was a limitation that we plan to address in the future.
